The pharmaceutical and the consumer durables sectors, which depend on China for imports, have not been impacted yet due to unrest in China with people protesting against lockdowns. But the lockdown could have an impact on the supply of components used in consumer durables if it continues for the next fortnight. In the pharmaceutical industry, Indian players import 66-70 per cent of their bulk drug requirements from China.
The current crisis has forced the government to announce measures to ensure that India becomes self-sustaining for any kind of bulk drug. The government says India will not depend on any other country for vital key ingredients for drugs within six years, reports Sheela Bhatt.
Apart from them, consignments of 11 top importers, including LG, Samsung, Toyota, Honda, and Siemens, will also be allowed entry, relieving them of the 100 per cent inspection rule.
Big pharma companies, however, said while it was true that formulation players would not rush to buy raw material, they could not afford losing customers.
This is the first mission by the Indian Speace Research Organisation this year.
The shortlist for the Architectural Photography Awards 2018 has been revealed. The awards are split into four categories: Exterior, Interior, Sense of Place, and Buildings in Use, with each comprising five finalists. The 20 photographs that make up the shortlist will be exhibited at the World Architecture Festival in Amsterdam between November 28 - 30, and an overall winner will be announced on the 30. Here are some of the brilliant photos in the shortlist.
Experts say while the increasing demand for a ban on Chinese goods might make for good optics, the reality is that India is still heavily dependent on that country in a wide range of industries like electronics, mobile devices, auto, pharma, telecom equipment, and fertilisers.
The Punjab government blames the slow growth on tax concessions in neighboring Himachal Pradesh and Haryana's proximity to Delhi.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances